 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4609 News |  |
| «12...46474849505152535455565758 |
- ||||| Soliris (eculizumab) / AstraZeneca
Trial initiation date: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) (clinicaltrials.gov) - Nov 17, 2013
P3, N=132, Recruiting, Sponsor: Alexion Pharmaceuticals
Initiation date: Jul 2013 --> Jan 2014
- ||||| Soliris (eculizumab) / AstraZeneca
Enrollment change: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) (clinicaltrials.gov) - Nov 17, 2013
P3, N=132, Recruiting, Sponsor: Alexion Pharmaceuticals
Initiation date: Jul 2013 --> Jan 2014 N=93 --> 132
- |||| Soliris (eculizumab) / AstraZeneca
Trial completion: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) (clinicaltrials.gov) - Aug 22, 2013
P2, N=60, Completed, Sponsor: Philip J. Rosenfeld, MD, PhD
N=93 --> 132 Active, not recruiting --> Completed
- Soliris (eculizumab) / AstraZeneca
New P2 trial: Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation (clinicaltrials.gov) - Aug 7, 2013
P2, N=24, Recruiting, Sponsor: Heeger, Peter, M.D.
- || Soliris (eculizumab) / AstraZeneca
Enrollment change: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=75, Completed, Sponsor: Alexion Pharmaceuticals
Active, not recruiting --> Completed N=170 --> 75
- | Soliris (eculizumab) / AstraZeneca
New P2 trial: Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation (clinicaltrials.gov) - Jul 8, 2013
P2, N=21, Recruiting, Sponsor: Brigham and Women's Hospital
- ||| Soliris (eculizumab) / AstraZeneca
Trial completion: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=75, Completed, Sponsor: Alexion Pharmaceuticals
N=170 --> 75 Recruiting --> Completed
- |||||||||| Soliris (eculizumab) / AstraZeneca
New P3 trial: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) (clinicaltrials.gov) - Jul 2, 2013
P3, N=132, Recruiting, Sponsor: Alexion Pharmaceuticals
- Soliris (eculizumab) / AstraZeneca
Trial withdrawal: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab (clinicaltrials.gov) - Mar 28, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Recruiting --> Withdrawn
- Soliris (eculizumab) / AstraZeneca
Enrollment change: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab (clinicaltrials.gov) - Mar 28, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Withdrawn N=10 --> 0
- Soliris (eculizumab) / AstraZeneca
Enrollment open: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury (clinicaltrials.gov) - Mar 14, 2013
P2, N=40, Recruiting, Sponsor: Russian Academy of Medical Sciences
N=10 --> 0 Not yet recruiting --> Recruiting
- Soliris (eculizumab) / AstraZeneca
New P2 trial: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) (clinicaltrials.gov) - Dec 27, 2012
P2, N=5, Recruiting, Sponsor: Alexion Pharmaceuticals
- Soliris (eculizumab) / AstraZeneca
New P2 trial: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury (clinicaltrials.gov) - Dec 25, 2012
P2, N=40, Recruiting, Sponsor: Russian Academy of Medical Sciences
- ||||| Soliris (eculizumab) / AstraZeneca
Enrollment change: Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) (clinicaltrials.gov) - Jul 2, 2012
P2/3, N=198, Completed, Sponsor: Alexion Pharmaceuticals
Not yet recruiting --> Recruiting N=400 --> 198
- ||||||| Soliris (eculizumab) / AstraZeneca
Trial completion: Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) (clinicaltrials.gov) - Jul 2, 2012
P2/3, N=198, Completed, Sponsor: Alexion Pharmaceuticals
N=400 --> 198 Active, not recruiting --> Completed
- | Soliris (eculizumab) / AstraZeneca
Enrollment closed: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome (clinicaltrials.gov) - Jun 10, 2012
P2, N=41, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Soliris (eculizumab) / AstraZeneca
Enrollment closed: aHUS: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (clinicaltrials.gov) - Jun 10, 2012
P2, N=15, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- || Soliris (eculizumab) / AstraZeneca
Trial initiation date: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=75, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Sep 2011 --> Mar 2012
- ||| Soliris (eculizumab) / AstraZeneca
Enrollment open: aHUS Observational Long Term Follow-Up (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=150, Enrolling by invitation, Sponsor: Alexion Pharmaceuticals
Initiation date: Sep 2011 --> Mar 2012 Not yet recruiting --> Enrolling by invitation
- ||||| Soliris (eculizumab) / AstraZeneca
New P2 trial: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor (clinicaltrials.gov) - Mar 28, 2012
P2, N=80, Recruiting, Sponsor: Alexion Pharmaceuticals
- Soliris (eculizumab) / AstraZeneca
New P1/2 trial: An Open Label Study of the Effects of Eculizumab in CD59 Deficiency (clinicaltrials.gov) - Feb 22, 2012
P1/2, N=5, Recruiting, Sponsor: Hadassah Medical Organization
- | Soliris (eculizumab) / AstraZeneca
Trial completion: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients (clinicaltrials.gov) - Dec 4, 2011
P2, N=27, Completed, Sponsor: Alexion Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- Soliris (eculizumab) / AstraZeneca
Trial completion: Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - Nov 17, 2011
P1/2, N=7, Completed, Sponsor: Alexion Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Soliris (eculizumab) / AstraZeneca
Enrollment change: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome (clinicaltrials.gov) - Nov 16, 2011
P2, N=41, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Active, not recruiting --> Completed N=30 --> 41
- | Soliris (eculizumab) / AstraZeneca
Enrollment change: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 16, 2011
P2, N=14, Completed, Sponsor: Alexion Pharmaceuticals
N=30 --> 41 N=24 --> 14
- | Soliris (eculizumab) / AstraZeneca
Trial completion: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 16, 2011
P2, N=14, Completed, Sponsor: Alexion Pharmaceuticals
N=24 --> 14 Active, not recruiting --> Completed
- | Soliris (eculizumab) / AstraZeneca
Enrollment open: A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant (clinicaltrials.gov) - Nov 7, 2011
P2, N=20, Recruiting, Sponsor: Schroppel, Bernd, M.D.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting